KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Safety and efficacy of adjunct dexamethasone in adults with herpes simplex virus encephalitis in the UK (DexEnceph): a multicentre, observer-blind, randomised, phase 3, controlled trial.Lancet NeurolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41579900无 PMCID2026-Feb0.98未发现恶性肿瘤人群证据。无 KM 图
JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC.Future Oncol已检查 1 张 PMC Figure,均未识别为 KM 图:Figure 1.:AI 判定为 flow diagram。PMID 41612885PMC128674522026-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Analysis of Plasma Epstein-Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122.Cancer Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:ROC 图;FIGURE 2:ROC 图;FIGURE 3:非 KM 图;FIGURE 4:森林图/亚组分析图。PMID 41631899PMC128668142026-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Study 19 (MCI186-19) Post Hoc Analyses.Muscle Nerve入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41653003PMC128820332026-Feb0.98未发现恶性肿瘤人群证据。无 KM 图
Generalizability of Edaravone Efficacy.Muscle NervePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41653008PMC128820292026-Feb0.98未发现恶性肿瘤人群证据。无 KM 图
Microbiological analysis and whole-genome sequencing of Neisseria gonorrhoeae from the microbiological failures in the international, zoliflodacin, phase 3, clinical trial for treatment of uncomplicated urogenital gonorrhoea: a retrospective, genomic, observational study.Lancet Microbe入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41655579无 PMCID2026-Feb0.98未发现恶性肿瘤人群证据。无 KM 图
GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial.Mult SclerPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41705515无 PMCID2026-Feb0.98未发现恶性肿瘤人群证据。无 KM 图
Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction cancer: KEYNOTE-859 Q-TWiST analysis.Immunotherapy疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41964430PMC131550062026-Feb0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Efficacy and safety outcomes from the MATISSE phase 3 trial of maternal bivalent RSVpreF vaccination among pregnant women vaccinated at 32 to 36 weeks of gestation.Swiss Med WklyPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41962084无 PMCID2026-Jan-310.98未发现恶性肿瘤人群证据。无 KM 图
Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial.RMD Open疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:非 KM 图。PMID 41617358PMC128875082026-Jan-300.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41211918无 PMCID2026-Jan-290.98未发现恶性肿瘤人群证据。无 KM 图
A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41604638无 PMCID2026-Jan-290.98未发现恶性肿瘤人群证据。无 KM 图
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41604639无 PMCID2026-Jan-290.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
The cost-effectiveness of using vilobelimab with immunomodulators to treat severely ill mechanically ventilated patients with COVID-19: A subgroup analysis of the PANAMO study.Am J Health Syst Pharm已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。PMID 40638782PMC128395332026-Jan-270.98未发现恶性肿瘤人群证据。无 KM 图
Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis.Blood AdvPMID 41056515PMC128288282026-Jan-270.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Potent P2Y12 Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI: The NEO-MINDSET Substudy.J Am Coll CardiolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41384891无 PMCID2026-Jan-270.98未发现恶性肿瘤人群证据。无 KM 图
[Efficacy and safety of triptorelin acetate microspheres for injection versus triptorelin acetate for injection in Chinese patients with endometriosis: a multicenter, randomized, double-blind, phase Ⅲ non-inferiority clinical trial].Zhonghua Fu Chan Ke Za ZhiPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41611266无 PMCID2026-Jan-250.98未发现恶性肿瘤人群证据。无 KM 图
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41448222无 PMCID2026-Jan-240.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41544643无 PMCID2026-Jan-240.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。无 KM 图
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.BloodPMID 41060326PMC128838562026-Jan-220.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Nivolumab for Resected Stage III or IV Melanoma at 9 Years.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41124198无 PMCID2026-Jan-220.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41564397无 PMCID2026-Jan-220.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Effectiveness and cost-effectiveness of ozone treatment in patients with paraesthesia (numbness, tingling) secondary to chemotherapy-induced peripheral neuropathy: randomized, triple-blind clinical trial (OzoParQT).BMC CancerPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41572235PMC129110772026-Jan-220.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.J Clin OncolPMID 41365333PMC127947222026-Jan-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。部分完成
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.J Clin OncolPMID 41370738PMC127947172026-Jan-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Paclitaxel-Coated Balloon for Treating In-Stent Restenosis in Racial and Ethnic Minority Patients: A Subanalysis From the AGENT IDE Trial.J Am Heart AssocPMID 41553096PMC129195182026-Jan-200.98未发现恶性肿瘤人群证据。已完成
Plitidepsin in combination with dexamethasone (ADMYRE trial) versus an external control arm of pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.Ann Hematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图。PMID 41545603PMC128112702026-Jan-170.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
PROthrombin complex concentrate versus fresh frozen Plasma for bleeding in adults undergoing HEart SurgerY (PROPHESY-2 trial): a phase III, randomised control trial in England and Wales.Trials已检查 1 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图。PMID 41546086PMC128956332026-Jan-170.98未发现恶性肿瘤人群证据。无 KM 图
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative Symptoms.Schizophr Bull疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:非 KM 图。PMID 40181715PMC128097792026-Jan-160.98未发现恶性肿瘤人群证据。无 KM 图
A phase III, randomised, double-blind, multi-dose, placebo- and naproxen-controlled study to evaluate the efficacy and safety of fasinumab in patients with pain due to osteoarthritis of the knee or hip.RMD Open疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:非 KM 图;Figure 3:非 KM 图;Figure 4:非 KM 图。PMID 41545313PMC128151512026-Jan-160.98未发现恶性肿瘤人群证据。无 KM 图
Cytisinicline for smoking cessation in individuals with self-reported COPD: a post hoc analysis of the ORCA-2 and ORCA-3 trials.Thorax已检查 1 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other。PMID 40962497PMC129116542026-Jan-150.98未发现恶性肿瘤人群证据。无 KM 图
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.Blood已检查 6 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;Figure 1:AI 判定为 flow diagram;Figure 2:生活质量量表图;Figure 3:生活质量量表图;Figure 4:生活质量量表图;另有 1 张未列出。PMID 40997297PMC128246482026-Jan-150.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Clinical safety of ultra-high-dose methylcobalamin in patients with amyotrophic lateral sclerosis: Open-label extension of a phase 2/3 randomized controlled study.J Neurol Sci入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41475066无 PMCID2026-Jan-150.98未发现恶性肿瘤人群证据。无 KM 图
Fremanezumab in Children and Adolescents with Episodic Migraine.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41534042无 PMCID2026-Jan-150.98未发现恶性肿瘤人群证据。无 KM 图
Variations in the Natural History of High-Risk HPV Types Following HPV-16/18 Bivalent Vaccination in Females Aged 18-45 Years.Nat CommunKM panel re-extraction failedPMID 41535287PMC129099332026-Jan-140.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma.Blood Adv疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 1.:非 KM 图;Figure 2.:非 KM 图;Figure 3.:森林图/亚组分析图;Figure 4.:森林图/亚组分析图。PMID 40990939PMC128052612026-Jan-130.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.JAMA已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other。PMID 41206969PMC125985802026-Jan-130.98未发现恶性肿瘤人群证据。无 KM 图
Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial.Ann HematolPMID 41521262PMC127910582026-Jan-120.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41337696无 PMCID2026-Jan-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41360064无 PMCID2026-Jan-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41371238无 PMCID2026-Jan-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial.LancetPMID 41391462PMC128122482026-Jan-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:森林图/亚组分析图。PMID 41391465PMC127842152026-Jan-100.98未发现恶性肿瘤人群证据。无 KM 图
Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension.Nat Commun已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:森林图/亚组分析图;Fig. 5:AI 判定为 other。PMID 41519901PMC128916922026-Jan-100.98未发现恶性肿瘤人群证据。无 KM 图
Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn's disease.J Crohns Colitis入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。PMID 41264726PMC127955992026-Jan-090.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Validating and leveraging non-SARS-CoV-2 respiratory infection as a negative control outcome in a phase 3 COVID-19 vaccine trial with extended observational follow-up.Am J Epidemiol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1::非 KM 图;Figure 2::非 KM 图;Figure 3::非 KM 图;Figure 4::非 KM 图。PMID 40838594PMC124486732026-Jan-080.98未发现恶性肿瘤人群证据。无 KM 图
Impact of dactylitis and enthesitis resolution on disease control in guselkumab-treated psoriatic arthritis patients with TNFi-IR: COSMOS post hoc analysis.Rheumatology (Oxford)PMID 40971670PMC128623822026-Jan-080.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2 years.Rheumatology (Oxford)疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1.:AI 判定为 flow diagram;Figure 2.:非 KM 图;Figure 3.:非 KM 图;Figure 4.:AI 判定为 other;Figure 5.:非 KM 图。PMID 40973471PMC128623732026-Jan-080.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Secukinumab in active lupus nephritis: results from a phase III randomized, placebo-controlled study (SELUNE) and an open-label extension study.Rheumatology (Oxford)PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41092316PMC128623662026-Jan-080.98未发现恶性肿瘤人群证据。无 KM 图
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41211925无 PMCID2026-Jan-080.98未发现恶性肿瘤人群证据。无 KM 图